Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double-blinded, placebo-controlled clinical trial

被引：55

作者：

Dastani, Mostafa ^{[1
]}

Rahimi, Hamid Reza ^{[2
,3
]}

Askari, Vahid Reza ^{[4
,5
,6
]}

Jaafari, Mahmoud Reza ^{[7
]}

Jarahi, Lida ^{[8
]}

Yadollahi, Asal ^{[1
]}

Rahimi, Vafa Baradaran ^{[1
]}

机构：

[1] Mashhad Univ Med Sci, Fac Med, Dept Cardiovasc Dis, Azadi Sq,Vakil Abad Highway, Mashhad 9177948564, Razavi Khorasan, Iran

[2] Mashhad Univ Med Sci, Vasc & Endovasc Surg Res Ctr, Mashhad, Razavi Khorasan, Iran

[3] Mashhad Univ Med Sci, Sch Med, Dept Med Genet & Mol Med, Mashhad, Razavi Khorasan, Iran

[4] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Razavi Khorasan, Iran

[5] Mashhad Univ Med Sci, Sch Persian & Complementary Med, Dept Pharmaceut Sci Persian Med, Mashhad, Razavi Khorasan, Iran

[6] Mashhad Univ Med Sci, Sch Persian & Complementary Med, Dept Persian Med, Mashhad, Razavi Khorasan, Iran

[7] Mashhad Univ Med Sci, Nanotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad, Razavi Khorasan, Iran

[8] Mashhad Univ Med Sci, Fac Med, Dept Community Med, Mashhad, Razavi Khorasan, Iran

来源：

BIOFACTORS | 2023年 / 49卷 / 01期

基金：

欧洲研究理事会;

关键词：

coronary artery disease; hs-CRP; lipoprotein a; nano-curcumin; type; 2; diabetes; C-REACTIVE PROTEIN; RISK; ATHEROSCLEROSIS; BIOAVAILABILITY; MELLITUS;

D O I：

10.1002/biof.1874

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Diabetes is one of the most common chronic diseases worldwide. Systemic inflammation (high-sensitivity C-reactive protein (hs-CRP)) and lipid metabolism disruption (lipoprotein A, LipoPr (a)) play a critical role in developing and progressing atherosclerosis and acute coronary syndrome in diabetic patients. The anti-oxidant and anti-inflammatory effects of curcumin have been emphasized previously. Therefore, we aimed to evaluate the impact of nano-curcumin on cardiovascular risk factors in type 2 diabetic patients with mild to moderate coronary artery disease (CAD). We performed a randomized, double-blinded, placebo-controlled clinical trial with type 2 diabetic patients (n = 64), and mild to moderate CAD (<70% stenosis in angiography). The patients received nano-curcumin (80 mg/day) or placebo along with optimal medications for 90 days. The biofactors, including hs-CRP and LipoPr (a), and lipid profile, were measured at the admission of patients and end of the study. Nano-curcumin significantly mitigated the hs-CRP and LipoPr (a) levels following 90 days of treatment (P < 0.001 and P = 0.043, respectively). In addition, the mean percentage of change (%Delta) in the hs-CRP and LipoPr (a) levels were meaningfully reduced in the nano-curcumin group compared to the placebo group (P < 0.001 and P = 0.007, respectively). Surprisingly, nano-curcumin notably propagated the number of patients with mild (34.35%) and moderate (62.5%) hs-CRP level category and strikingly diminished the number of patients with severe hs-CRP level category (3.125%) compared to the placebo group (P = 0.016). Nano-curcumin (80 mg/day) might prevent atherosclerosis progression and, in terms of attenuating hs-CRP levels as an inflammation index, succedent cardiovascular events in diabetic heart patients.

引用

页码：108 / 118

页数：11

共 35 条

[1] A Novel Combination of ω-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study [J].